公开(公告)号：US20240350472A1

公开(公告)日：2024-10-24

申请号：US18760551

申请日：2024-07-01

Applicant: Pathyil Damoderam Krishna Kumar

Inventor： Pathyil Damoderam Krishna Kumar

IPC: A61K31/4468 ,  A61B1/32 ,  A61B10/00 ,  A61B17/42 ,  A61K31/215 ,  A61K31/5575 ,  A61L31/00 ,  A61M29/00 ,  A61M31/00 ,  A61P29/00

CPC classification number: A61K31/4468 ,  A61B1/32 ,  A61B17/42 ,  A61K31/215 ,  A61K31/5575 ,  A61L31/005 ,  A61M29/00 ,  A61P29/00 ,  A61B2010/0074 ,  A61B2017/4225 ,  A61B2217/005 ,  A61B2217/007 ,  A61M31/00

Abstract: Synergistic compositions for use in treatment during gynecological procedures are provided. Synergistic compositions that enable practitioners to perform gynecological procedures without pain or bleeding to patients are provided.

公开(公告)号：US20240350142A1

公开(公告)日：2024-10-24

申请号：US18558325

申请日：2022-04-27

Applicant: SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANT'ANNA

Inventor： Vincenzo LIONETTI ,  Silvestro MICERA ,  Eugenio REDOLFI RIVA ,  Ivo STRAUSS

IPC: A61B17/11 ,  A61B17/00 ,  A61L31/00 ,  A61L31/04 ,  A61L31/10 ,  A61L31/16 ,  A61N1/05

CPC classification number: A61B17/1128 ,  A61L31/005 ,  A61L31/041 ,  A61L31/10 ,  A61L31/16 ,  A61B2017/00004 ,  A61N1/0556

Abstract: The present invention relates to a biocompatible and biodegradable tubular guide channel useful as a regenerative nerve interface to assist nerve regeneration and to support thin film electrodes capable of recording and stimulating electrical signals from the regenerated nerve. The invention further relates to a device containing the guide channel and thin film electrode, and to the process of manufacturing the guide channel and the device.

公开(公告)号：US12109332B2

公开(公告)日：2024-10-08

申请号：US18386896

申请日：2023-11-03

Applicant: The Regents of the University of California ,  Silq Technologies Corporation

Inventor： Brian T. McVerry ,  Ethan Rao ,  Richard B. Kaner ,  Na He

IPC: A61L31/00 ,  A61L29/08 ,  C08F220/30 ,  C08F220/34 ,  C08F220/38 ,  C08F293/00 ,  C09D5/00 ,  C09D153/00

CPC classification number: A61L31/00 ,  A61L29/085 ,  C08F220/30 ,  C08F220/34 ,  C08F220/382 ,  C08F293/005 ,  C09D5/00 ,  C09D153/00 ,  A61L2420/02 ,  C08F2438/01

Abstract: Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

公开(公告)号：US20240245514A1

公开(公告)日：2024-07-25

申请号：US18436900

申请日：2024-02-08

Applicant: Howmedica Osteonics Corp.

Inventor： Sonny Sheth ,  David Arazawa ,  j. Brook Burley ,  Sarah Elizabeth Smith ,  Matthew B. Havener ,  James San Antonio ,  Marc Gilles Long

IPC: A61F2/28 ,  A61F2/30 ,  A61F2/46 ,  A61L27/02 ,  A61L27/26 ,  A61L27/36 ,  A61L27/40 ,  A61L31/00 ,  A61L31/12 ,  A61L31/16

CPC classification number: A61F2/28 ,  A61F2/30767 ,  A61F2/4601 ,  A61L27/02 ,  A61L27/025 ,  A61L27/3645 ,  A61L27/365 ,  A61L27/40 ,  A61L31/005 ,  A61L31/127 ,  A61L31/16 ,  A61F2002/2835 ,  A61F2002/3006 ,  A61F2002/30062 ,  A61F2002/3093 ,  A61F2/30965 ,  A61L27/26 ,  A61L2420/02 ,  A61L2420/06 ,  C12N2533/18

Abstract: A bioactive filamentary structure includes a sheath coated with a mixture of synthetic bone graft particles and a polymer solution forming a scaffold structure. In forming such a structure, synthetic bone graft particles and a polymer solution are applied around a filamentary structure. A polymer is precipitated from the polymer solution such that the synthetic bone graft particles and the polymer coat the filamentary structure and the polymer is adhered to the synthetic bone graft particles to retain the graft particles.

公开(公告)号：US12042557B2

公开(公告)日：2024-07-23

申请号：US17121359

申请日：2020-12-14

Applicant: Intarcia Therapeutics, Inc.

Inventor： Thomas R. Alessi ,  Kenneth Luskey

IPC: A61L31/00 ,  A61F5/00 ,  A61K9/00 ,  A61K38/26 ,  A61L27/54 ,  A61M5/142 ,  A61K38/00 ,  A61M5/145

CPC classification number: A61K9/0004 ,  A61F5/0013 ,  A61K9/0024 ,  A61K38/26 ,  A61L27/54 ,  A61M5/14276 ,  A61K38/00 ,  A61M2005/14513 ,  A61M2205/04

Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

公开(公告)号：US20240226390A9

公开(公告)日：2024-07-11

申请号：US18011616

申请日：2022-06-14

Applicant: CNLD CO., LTD. ,  UIF (University Industry Foundation), Yonsei Uneversity

Inventor： Sung Joo Hwang ,  Dong Min Kim ,  Ji Eun Kim ,  Yeon Ju Choi ,  Yong Kyung Hwang

IPC: A61L31/04 ,  A61L31/00 ,  A61L31/14

CPC classification number: A61L31/042 ,  A61L31/005 ,  A61L31/14

Abstract: Disclosed is an anti-adhesion agent composition which uses a high molecular weight compound having biocompatibility and an oil derived from animals, plants, and minerals so as to improve low viscosity and low strength, which are problems of existing anti-adhesion agents, and prevent adhesion between living tissues. The anti-adhesion composition according to the present disclosure performs a physical barrier function through simple mixing of a polymer material, serving as a physical barrier in its anti-adhesion effect, and a solvent, and remains in the body for a certain period of time, then decomposes, absorbs, and is excreted. The anti-adhesion composition does not interfere with the healing of the wound after surgery, and exhibits an excellent effect of convenient application to the surgical site.

公开(公告)号：US12029636B2

公开(公告)日：2024-07-09

申请号：US17902689

申请日：2022-09-02

Applicant: Arizona Board of Regents on Behalf of the University of Arizona

Inventor： Klearchos K. Papas

IPC: A61L31/00 ,  A61F2/02 ,  A61L27/22 ,  A61L27/52 ,  A61L27/54

CPC classification number: A61F2/022 ,  A61L27/225 ,  A61L27/227 ,  A61L27/52 ,  A61L27/54 ,  A61F2220/0075

Abstract: Systems featuring two or more encapsulation devices stacked together. The encapsulation devices house cells, such as but not limited to islet cells or stem cell derived beta cells or the like. e.g., for regulating blood glucose, or other cells or spheroids that can produce and release a therapeutic agent that is useful in the body, etc. The system may feature oxygen delivery, or in some cases no exogenous oxygen is delivered and vascularization of the device can help provide oxygen and other needed nutrient to the cells. The system of the present invention may be used in conjunction with other therapies such as an artificial pancreas. Stacking the devices with blood vessel formation around and in between them may allow for a decrease in the footprint that would be needed for implantation.

公开(公告)号：US20240216577A1

公开(公告)日：2024-07-04

申请号：US18609457

申请日：2024-03-19

Applicant: KM Biologics Co, Ltd.

Inventor： Hideki SAGA ,  Minako INUI ,  Noriko OGURA

IPC: A61L27/22 ,  A61K38/36 ,  A61L27/36 ,  A61L27/56 ,  A61L27/58 ,  A61L31/00 ,  A61L31/04 ,  A61L31/14

CPC classification number: A61L27/22 ,  A61K38/36 ,  A61L27/36 ,  A61L27/56 ,  A61L27/58 ,  A61L31/005 ,  A61L31/043 ,  A61L31/146 ,  A61L2430/20

Abstract: A problem to be solved by the present invention is to provide a fibrosis inhibitor that solves the problem of inhibiting fibrosis of an organ or tissue surface, and especially of inhibiting fibrosis of an epicardial surface. Furthermore, by inhibiting fibrosis, the present invention prevents or reduces subsequent development of adhesions to avoid organ or tissue damage during re-operation. Provided is a fibrosis inhibitor for inhibiting fibrosis of a tissue by fixing a biocompatible polymer to a tissue where it is desirable to inhibit fibrosis.

公开(公告)号：US11998665B2

公开(公告)日：2024-06-04

申请号：US16084059

申请日：2017-03-13

Applicant: ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING AND CELL BASED TECHNOLOGIES & THERAPIES (A4TEC)

Inventor： Rui Luis Gonçalves Dos Reis ,  Ana Rita Cruz Duarte ,  Alexandre António Antunes Barros ,  Estêvão Augusto Rodrigues De Lima ,  Carlos André Ribeiro Oliveira

IPC: A61L31/00 ,  A61F2/04 ,  A61K31/337 ,  A61K31/704 ,  A61K31/7068 ,  A61K47/36 ,  A61K47/42 ,  A61L31/04 ,  A61L31/14 ,  A61L31/16 ,  A61L31/18

CPC classification number: A61L31/148 ,  A61F2/04 ,  A61K31/337 ,  A61K31/704 ,  A61K31/7068 ,  A61K47/36 ,  A61K47/42 ,  A61L31/041 ,  A61L31/16 ,  A61L31/18 ,  A61F2002/048 ,  A61L2300/416

Abstract: The present disclosure relates to biodegradable ureteral stents comprising an anti-cancer drug, and to a composition for use in medicine that may be used to ensure patency of a channel, namely a mammal ureter, for example, an obstructed ureter by a urinary stone, neoplasia or by a surgical procedure. The biodegradable ureteral stents (BUS) disclosed in the present disclosure unexpectedly allow a proper release of anti-cancer drugs, thus extending the duration of the treatment and increasing the efficacy of the treatment.

公开(公告)号：US11992508B2

公开(公告)日：2024-05-28

申请号：US15522441

申请日：2015-10-28

Applicant: BIOVOTEC AS

Inventor： Ralf Schmidt ,  Henri-Pierre Suso ,  Enda Kenny

IPC: A61K35/57 ,  A61K9/14 ,  A61L15/40 ,  A61L15/60 ,  A61L26/00 ,  A61L27/36 ,  A61L31/00 ,  A61L31/08 ,  A61P17/02

CPC classification number: A61K35/57 ,  A61K9/14 ,  A61L15/40 ,  A61L15/60 ,  A61L26/0023 ,  A61L26/0057 ,  A61L26/008 ,  A61L27/3604 ,  A61L31/005 ,  A61L31/08 ,  A61P17/02 ,  A61L2300/30 ,  A61L2300/404 ,  A61L2300/41 ,  A61L2300/412 ,  A61L15/60 ,  C08L5/04 ,  A61L26/008 ,  C08L5/04

Abstract: The invention provides a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 μm for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. The invention further provides pharmaceutical compositions, wound dressings and implantable medical devices comprising the micronized ESM-containing particles for use in said treatments. The invention still further provides methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices comprising the same.